Article Text
Commentary
Anti-TNF antibody therapy in Crohn's disease: the risk of a switch
Statistics from Altmetric.com
Footnotes
Linked article 300755.
Competing interests JP has been consultant for Abbott, MSD, Pfizer and Novartis; ER has been consultant for Abbott and MSD; IO has been consultant for Prometheus. JP has received speaker fees from Abbott, MSD, Ferring and Shire; ER has received speaker fees from Abbott and MSD. JP, ER and IO have received unrestricted research grants from Abbott and MSD.
Provenance and peer review Commissioned; internally peer reviewed.